JP2009536181A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009536181A5 JP2009536181A5 JP2009508383A JP2009508383A JP2009536181A5 JP 2009536181 A5 JP2009536181 A5 JP 2009536181A5 JP 2009508383 A JP2009508383 A JP 2009508383A JP 2009508383 A JP2009508383 A JP 2009508383A JP 2009536181 A5 JP2009536181 A5 JP 2009536181A5
- Authority
- JP
- Japan
- Prior art keywords
- represent
- compound
- strain
- formula
- macbecin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 claims description 25
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 10
- 238000000034 method Methods 0.000 claims 10
- 229930195248 Macbecin Natural products 0.000 claims 9
- PLTGBUPHJAKFMA-UHFFFAOYSA-N Macbecin I Natural products N1C(=O)C(C)=CC=CC(C)C(OC(N)=O)C(C)=CC(C)C(OC)C(OC)CC(C)C(OC)C2=CC(=O)C=C1C2=O PLTGBUPHJAKFMA-UHFFFAOYSA-N 0.000 claims 9
- PLTGBUPHJAKFMA-BMJWZTMLSA-N [(2r,3s,5s,6r,7s,8e,10r,11s,12z,14e)-2,5,6-trimethoxy-3,7,9,11,15-pentamethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](C)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O PLTGBUPHJAKFMA-BMJWZTMLSA-N 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000007858 starting material Substances 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000000415 inactivating effect Effects 0.000 claims 3
- -1 prnisone Chemical compound 0.000 claims 3
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims 2
- 108010069236 Goserelin Proteins 0.000 claims 2
- 102000003964 Histone deacetylase Human genes 0.000 claims 2
- 108090000353 Histone deacetylase Proteins 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 2
- 229960002932 anastrozole Drugs 0.000 claims 2
- 230000001851 biosynthetic effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 2
- 235000008191 folinic acid Nutrition 0.000 claims 2
- 239000011672 folinic acid Substances 0.000 claims 2
- 229960002913 goserelin Drugs 0.000 claims 2
- 229960001691 leucovorin Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims 2
- 229960004296 megestrol acetate Drugs 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims 1
- AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 claims 1
- FXEMCOVVTSYFRJ-UHFFFAOYSA-N 3-amino-2,5,6-trifluorobenzoic acid Chemical compound NC1=CC(F)=C(F)C(C(O)=O)=C1F FXEMCOVVTSYFRJ-UHFFFAOYSA-N 0.000 claims 1
- RYLBYCHERDTVAY-UHFFFAOYSA-N 3-amino-5-fluorobenzoic acid Chemical compound NC1=CC(F)=CC(C(O)=O)=C1 RYLBYCHERDTVAY-UHFFFAOYSA-N 0.000 claims 1
- YQXQZKKJAITNKW-UHFFFAOYSA-N 5-amino-2,3-difluorobenzoic acid Chemical compound NC1=CC(F)=C(F)C(C(O)=O)=C1 YQXQZKKJAITNKW-UHFFFAOYSA-N 0.000 claims 1
- WYGAIOJWQDRBRJ-UHFFFAOYSA-N 5-amino-2-fluorobenzoic acid Chemical compound NC1=CC=C(F)C(C(O)=O)=C1 WYGAIOJWQDRBRJ-UHFFFAOYSA-N 0.000 claims 1
- 241000123665 Actinosynnema mirum Species 0.000 claims 1
- 241000143227 Actinosynnema pretiosum Species 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 229930192392 Mitomycin Natural products 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940121647 egfr inhibitor Drugs 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 229940124302 mTOR inhibitor Drugs 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- 238000002625 monoclonal antibody therapy Methods 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 239000003909 protein kinase inhibitor Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 229960002119 raloxifene hydrochloride Drugs 0.000 claims 1
- BKXVVCILCIUCLG-UHFFFAOYSA-N raloxifene hydrochloride Chemical compound [H+].[Cl-].C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 BKXVVCILCIUCLG-UHFFFAOYSA-N 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 229960001796 sunitinib Drugs 0.000 claims 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 229960005026 toremifene Drugs 0.000 claims 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims 1
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- 229960004355 vindesine Drugs 0.000 claims 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 1
- 229960000237 vorinostat Drugs 0.000 claims 1
- 0 C[C@](CCCC(C)=CC[C@@](*)[C@](C[C@](C)[C@](c1cc(F)cc(N2)c1)O)OC)CCC=C(C)C2=O Chemical compound C[C@](CCCC(C)=CC[C@@](*)[C@](C[C@](C)[C@](c1cc(F)cc(N2)c1)O)OC)CCC=C(C)C2=O 0.000 description 1
Images
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0609132.6A GB0609132D0 (en) | 2006-05-09 | 2006-05-09 | Novel compounds and methods for their production |
| GB0616637A GB0616637D0 (en) | 2006-08-22 | 2006-08-22 | Novel compounds and methods for their production |
| GBGB0622341.6A GB0622341D0 (en) | 2006-11-09 | 2006-11-09 | Novel compounds and methods for their preparation |
| PCT/EP2007/054476 WO2007128829A2 (en) | 2006-05-09 | 2007-05-09 | 18,21-didesoxymacbecin derivatives for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009536181A JP2009536181A (ja) | 2009-10-08 |
| JP2009536181A5 true JP2009536181A5 (cg-RX-API-DMAC7.html) | 2010-07-01 |
Family
ID=38476939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009508383A Abandoned JP2009536181A (ja) | 2006-05-09 | 2007-05-09 | 癌治療用の１８，２１−ジデスオキシマクベシン誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20090253667A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1928837A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2009536181A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20090005376A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007247121A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0711093A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2651558A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2008014278A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007128829A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090078822A (ko) * | 2006-11-09 | 2009-07-20 | 바이오티카 테크놀로지 리미티드 | 암 치료를 위한 18, 21-디데스옥시막베신 유도체 |
| US7855192B2 (en) | 2007-01-26 | 2010-12-21 | Kosan Biosciences, Inc. | Macrolactams by engineered biosynthesis |
| EP2129662A2 (en) * | 2007-03-01 | 2009-12-09 | Biotica Technology Limited | C21-deoxy ansamycin derivatives as antitumor agents |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| CN101869138B (zh) * | 2010-05-28 | 2012-05-30 | 江苏省农业科学院 | 一种微胶囊发酵剂储存保护液 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005009345A2 (en) * | 2003-06-13 | 2005-02-03 | Kosan Biosciences, Inc. | 2-desmethyl ansamycin compounds |
| JP2009521423A (ja) * | 2005-12-24 | 2009-06-04 | バイオチカ テクノロジー リミテッド | 抗癌剤として有用な２１−デオキシマクベシン類似体 |
-
2007
- 2007-05-09 CA CA002651558A patent/CA2651558A1/en not_active Abandoned
- 2007-05-09 US US12/296,542 patent/US20090253667A1/en not_active Abandoned
- 2007-05-09 KR KR1020087027545A patent/KR20090005376A/ko not_active Withdrawn
- 2007-05-09 JP JP2009508383A patent/JP2009536181A/ja not_active Abandoned
- 2007-05-09 AU AU2007247121A patent/AU2007247121A1/en not_active Abandoned
- 2007-05-09 MX MX2008014278A patent/MX2008014278A/es not_active Application Discontinuation
- 2007-05-09 BR BRPI0711093-6A patent/BRPI0711093A2/pt not_active IP Right Cessation
- 2007-05-09 EP EP07728928A patent/EP1928837A2/en not_active Withdrawn
- 2007-05-09 WO PCT/EP2007/054476 patent/WO2007128829A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2590778T3 (es) | Compuestos de quinolina sustituida | |
| JP2009536181A5 (cg-RX-API-DMAC7.html) | ||
| US9289415B2 (en) | Treatment of cancer | |
| US11458126B2 (en) | DHODH inhibitor for use in treating hematologic cancers | |
| CN101563079B (zh) | 钠通道阻滞剂在制备治疗由于化疗而产生的神经病理性疼痛的药物中的用途 | |
| MX2020000268A (es) | Agonista de fxr. | |
| JPWO2008108386A1 (ja) | 医薬組成物 | |
| JP2017511321A5 (cg-RX-API-DMAC7.html) | ||
| US10406150B2 (en) | Method for treatment of primary hormone resistant endometrial and breast cancers | |
| WO2017127442A1 (en) | Methods for treating cancer with rorgamma inhibitors | |
| WO2013059944A1 (en) | Epigenetic regulators and uses thereof | |
| KR20150081422A (ko) | mTOR 경로 관련 질병 치료를 위한 화합물 | |
| JP7442439B2 (ja) | Ｋｄｍ４阻害剤 | |
| RU2409364C2 (ru) | 3,11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИН ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНОГО ЗАБОЛЕВАНИЯ ИЛИ ВОСПАЛЕНИЯ | |
| JP2009536934A5 (cg-RX-API-DMAC7.html) | ||
| WO2017112823A1 (en) | Targeted selection of patients for treatment with specific cortistatin derivatives | |
| CN105147667B (zh) | Skp1癌蛋白及其靶向药物在肿瘤治疗中的应用 | |
| JP2010509306A5 (cg-RX-API-DMAC7.html) | ||
| JP2018531995A5 (cg-RX-API-DMAC7.html) | ||
| US11952353B2 (en) | STAT3 transcription factor inhibitors and methods of using the same | |
| JP7636322B2 (ja) | 癌を処置するためのマドラシン誘導体化合物、組成物およびこれらの使用 | |
| US20250186446A1 (en) | Organic compounds | |
| CN1949977A (zh) | 抗冠状病毒化合物 | |
| EP3179998B1 (en) | Compounds for the treatment of hpv-induced carcinoma | |
| WO2019246158A1 (en) | Methods of treating cancer with carbenoxolone |